| Title |
Acute effects of the selective cholinergic channel activator (nicotinic agonist) ABT-418 in Alzheimer’s disease
|
|---|---|
| Published in |
Psychopharmacology, March 1999
|
| DOI | 10.1007/s002130050897 |
| Pubmed ID | |
| Authors |
Alexandra Potter, June Corwin, Jason Lang, Melissa Piasecki, Robert Lenox, P. A. Newhouse |
| Abstract |
To explore further the potential for cognitive enhancement utilizing nicotinic stimulation in Alzheimer's disease (AD), six otherwise healthy subjects with moderate AD received placebo and three doses (6, 12, and 23 mg) of the novel selective cholinergic channel activator (ChCA) (nicotinic agonist) ABT-418 over 6 h in a double-blind, within-subjects, repeated-measures design. Subjects showed significant improvements in total recall and a decline in recall failure on a verbal learning task. Qualitatively similar improvements were seen in non-verbal learning tasks such as spatial learning and memory, and repeated acquisition. No significant behavioral, vital sign, or physical side effects were seen. These results confirm that stimulating central nicotinic receptors has acute cognitive benefit in AD patients. These findings suggest that selective ChCAs have a potential therapeutic role in dementing disorders, and that further studies with this or similar agents in AD and/or Parkinson's disease are warranted. |
Mendeley readers
The data shown below were compiled from readership statistics for 66 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 2% |
| Australia | 1 | 2% |
| Unknown | 64 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 11 | 17% |
| Researcher | 11 | 17% |
| Student > Master | 10 | 15% |
| Student > Bachelor | 7 | 11% |
| Student > Postgraduate | 4 | 6% |
| Other | 9 | 14% |
| Unknown | 14 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 10 | 15% |
| Agricultural and Biological Sciences | 9 | 14% |
| Psychology | 9 | 14% |
| Neuroscience | 6 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 8% |
| Other | 8 | 12% |
| Unknown | 19 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 February 2014.
All research outputs
#3,798,287
of 25,373,627 outputs
Outputs from Psychopharmacology
#930
of 5,320 outputs
Outputs of similar age
#2,926
of 35,892 outputs
Outputs of similar age from Psychopharmacology
#9
of 44 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 5,320 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.0. This one has done well, scoring higher than 80% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 35,892 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 87% of its contemporaries.
We're also able to compare this research output to 44 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 77% of its contemporaries.